Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 11, Issue 2, 2008, Pages

  Matsuo, Kazuhiro ^a   Azuma, Minako ^a   Kasai, Maki ^b   Hanji, Itsuka ^a   Kimura, Itsuki ^a   Kosugi, Takayoshi ^a   Suga, Noriko ^a   Satoh, Mitsutoshi ^b  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; META ANALYSIS; PRESCRIPTION; RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; META-ANALYSIS AS TOPIC; PRESCRIPTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 65349133483     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Forrest, C.H. Ballow, D.E. Nix, M.C. Birmingham, J.J. Schentag, Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin-Antimicrob. Agent Chemother., 37, 1065-1072 (1993).
2. J. Sander, Fluoroquinolones--a new and important group of antimicrobial agents. Tidsskr Nor Laegeforen, 112, 346-349 (1992).
3. R.J. Fallon, W.M. Brown, In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin. J Antimicrob Chemother., 15, 787-789 (1985).
4. W. Klietmann, J. Focht, K. Nösner, Comparative in vitro activity of ciprofloxacin against aerobic and anaerobic bacteria from clinical isolates. Arzneimittelforschung, 37, 661-666 (1987).
5. R. Reina, E. Estenssoro, G. Sáenz, H.S. Canales, R. Gonzalvo, G. Vidal, G. Martins, A. Das Neves, O. Santander, Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med., 31, 1058-1065 (2005).
6. G. Höffken, M.S. Niederman, Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest., 122, 2183-2196 (2002).
7. M.M. Sánchez-Recio, C.I. Colino, A. Sánchez-Navarro, A retrospective analysis of pharmacokinetic /pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J Antimicrob Chemother., 45, 321-328 (2000).
8. C.E. Thorburn, D.I. Edwards, The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J Antimicrob Chemother., 48, 15-22 (2001).
9. M.J. Montgomery, P.M. Beringer, A. Aminimanizani, S.G. Louie, B.J. Shapiro, R. Jelliffe, M.A. Gill, Population Pharmacokinetics and use of Monte Carlo Simulation to evaluate Currently recommended dosing Regiments of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob. Agent Chemother., 45, 3468-3473 (2001).
10. S. Kohno, T. Matsushima, A. Saito, K. Nakata, K. Yamaguchi, A. Watanabe, N. Aoki, H. Goto, K. Suzuki, K. Sekizawa, K. Soma, T. Nagatake, K. Mikasa, The Japanese Respiratory Society guidelines for management of respiratory infections (2002). The Japanese Respiratory Society.
11. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, seventh edition. M11-A7. Wayne, PA: CLSI (2007).
12. D.W. Cockcroft, M. H Gault., Prediction of Creatinine from Serum Creatinine. Nephron, 16, 31-41 (1976).
13. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, J.J. Schentag, Pharmacodynamics of intravenous Ciprofloxacin in Seriously ill patients. Antimicrob. Agent Chemother., 37, 1073-1081 (1993).
14. A.A. Firsov, S.H. Zinner, I. Yu Lubenko, S.N. Vostrov, Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents., 16, 407-414 (2000).
15. M.W. Garrison, Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis., 54, 51-56 (2006).
16. M.D. Sánchez Navarro, C. Coloma Milano, A. Zarzuelo Castañeda, M.L. Sayalero Marinero, A. Sánchez-Navarro, Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. Clin Pharmacokinet., 41, 1213-1220 (2002).